Top Page
Genetic Signatures Ltd.
(Sydney:GSS)
Genetic Signatures Ltd. (GSS) vs. iShares MSCI Australia ETF (EWA)
Genetic Signatures Ltd. Business Overview & Revenue Model
Genetic Signatures Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.90M | 15.90M | 9.77M | 16.94M | 35.42M | 28.28M |
| Gross Profit | -2.39M | 7.78M | 4.31M | -12.74M | 7.21M | 4.27M |
| EBITDA | -15.87M | -16.08M | -19.82M | -13.14M | 4.70M | 3.22M |
| Net Income | -20.10M | -20.10M | -17.86M | -14.05M | 3.06M | 1.76M |
Balance Sheet | ||||||
| Total Assets | 54.63M | 54.63M | 67.29M | 49.08M | 59.65M | 54.05M |
| Cash, Cash Equivalents and Short-Term Investments | 31.30M | 31.30M | 36.25M | 16.35M | 36.90M | 30.12M |
| Total Debt | 791.00K | 791.00K | 1.22M | 0.00 | 34.00K | 399.00K |
| Total Liabilities | 4.54M | 4.54M | 6.18M | 6.16M | 4.85M | 4.71M |
| Stockholders Equity | 50.09M | 50.09M | 61.10M | 42.91M | 54.80M | 49.34M |
Cash Flow | ||||||
| Free Cash Flow | -12.94M | -13.19M | -14.91M | -20.55M | 6.82M | -784.00K |
| Operating Cash Flow | -12.29M | -12.29M | -10.12M | -12.45M | 9.81M | 4.20M |
| Investing Cash Flow | -24.30M | -24.30M | -4.79M | -8.09M | -2.99M | -4.98M |
| Financing Cash Flow | 7.79M | 7.79M | 34.81M | -23.00K | -101.00K | -190.00K |
Genetic Signatures Ltd. Technical Analysis
Genetic Signatures Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$51.74M | 27.46 | 98.18% | ― | 11.93% | 2.39% | |
53 Neutral | AU$50.59M | -13.18 | -501.54% | ― | ― | 56.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$44.17M | -6.06 | -97.79% | ― | ― | 23.85% | |
42 Neutral | AU$154.53M | -14.60 | -111.23% | ― | 12.96% | 40.81% | |
40 Underperform | AU$37.48M | -1.83 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$51.38M | -5.78 | -37.78% | ― | 2.33% | 12.50% |
Genetic Signatures Ltd. Corporate Events
Genetic Signatures reported unaudited second-quarter FY26 sales of $3.3 million, reflecting a seasonal downturn in respiratory testing in Australia, with revenue contributions now coming from Australia, EMEA and the US and a rising share from international markets. Customer receipts reached $4.6 million and net operating cash inflow was $1.8 million, bolstered by an Australian R&D tax incentive, leaving the company with a strong total cash and term deposit position of $29.7 million at 31 December 2025 to fund ongoing operations and development. Operationally, the company advanced implementation of its EasyScreen™ Gastrointestinal Parasite Detection Kit at three initial US customer sites that are now acting as reference centres to drive further adoption, while in the UK its gastrointestinal test kits are gaining momentum with National Health Service trusts, supported by positive clinical data and increased usage in infection control and outbreak prevention. The company also continued development of an automated, high-throughput integrated instrument and software platform, including procurement of a non-customised instrument to expand its 3base® infectious disease testing menu, positioning it for future product launches and potential growth in key international markets.
The most recent analyst rating on (AU:GSS) stock is a Sell with a A$0.22 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Limited announced the upcoming departure of CEO Allison Rossiter, who will leave in February 2026 to join a global pharmaceutical company. The company is actively searching for a new CEO and has interim leadership plans in place to ensure continuity. The leadership transition is seen as an opportunity to strengthen the management team and focus on advancing U.S. market opportunities. The recruitment for a new CFO is also underway, highlighting a period of strategic leadership changes aimed at enhancing the company’s capabilities and market positioning.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Limited announced a change in the director’s interest, with Anne Lockwood acquiring 250,000 Restricted Rights as approved at the company’s Annual General Meeting. This change reflects the company’s ongoing commitment to align its leadership’s interests with its strategic goals, potentially impacting its governance and stakeholder relations positively.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Ltd. announced the cessation of 150,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure, potentially affecting investor perceptions and market positioning.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Ltd held its 2025 Annual General Meeting, where resolutions were put to shareholders, resulting in the re-election of directors and approval of remuneration-related resolutions. These outcomes indicate continued support for the company’s leadership and strategic direction, potentially impacting its market positioning and stakeholder confidence positively.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Ltd announced the resignation of its Chief Financial and Operating Officer, Karl Pechmann, effective January 30, 2026. Pechmann has been instrumental in enhancing the company’s financial management and operational performance since joining in June 2023. The company has initiated a search for his successor to ensure continued operational stability. CEO Allison Rossiter praised Pechmann’s contributions, noting his leadership during challenging times and his role in positioning the company for future growth.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Ltd. announced the issuance of 1,016,859 performance rights as part of an employee incentive scheme. This move is expected to align employee interests with company goals, potentially enhancing productivity and commitment, and may positively impact the company’s market position and stakeholder value.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Ltd has updated the remuneration for its CEO, Allison Rossiter, with a new base salary of A$515,000 per annum and a long-term incentive plan involving performance rights. These changes, effective from October 2025, are part of a board review and aim to align the CEO’s compensation with long-term service and performance goals.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.